Evrópusambandið - spænska - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - anagrelide - trombocitemia, esencial - agentes antineoplásicos - xagrid está indicado para la reducción del conteo de plaquetas elevado en pacientes de riesgo esenciales-trombocitopenia (et) que son intolerantes a la terapia actual o cuyas plaquetas elevadas cuentas no se reducen a un nivel aceptable en su terapia actual. en riesgo patientan en riesgo de et se define por una o más de las siguientes características:>de 60 años de edad;o un recuento de plaquetas >1000 x 109/l o;una historia de thrombohaemorrhagic eventos.

Evrópusambandið - spænska - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - inmunosupresores - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Venesúela - spænska - Instituto Nacional de Higiene

calox international, c.a. - rosuvastatina - tabletas recubiertas - 10 mg

Venesúela - spænska - Instituto Nacional de Higiene

calox international, c.a. - rosuvastatina - tabletas recubiertas - 20 mg

Evrópusambandið - spænska - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacunas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.

Evrópusambandið - spænska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mieloma múltiple - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - spænska - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolismo de aminoácidos, errores congénitos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Evrópusambandið - spænska - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - antihemorrágicos - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

Evrópusambandið - spænska - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - infecciones por citomegalovirus - antivirales para uso sistémico - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antivirales.

Evrópusambandið - spænska - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mieloma múltiple - agentes antineoplásicos - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.